Abstract:The effects of the second‐generation antipsychotic risperidone (RIS) on reactive oxygen species (ROS) and microglia were analyzed using a mouse ketamine (KET) model of schizophrenia. Compared to KET‐treated mice, KET/RIS‐treated mice exhibited lower gene expression of the ROS‐generating enzyme (Nox2), and higher expression of antioxidant enzymes (Ho‐1 and Gclc). Three types of microglia were defined by hierarchical cluster analysis: resting‐ramified (type I) in control mice, moderately ramified (type II) in KET‐treated mice, and hyper‐ramified (type III) in KET/RIS‐treated mice. In vitro ROS assay showed that RIS reduced the production of microglial ROS induced by KET. Notably, antioxidant compounds (N‐Acetyl‐L‐cysteine [NAC] and GSK 2795039 [GSK]) alleviated schizophrenia‐like behaviors induced by KET, suggesting a promising direction for the development of novel treatments for schizophrenia. Recent studies have highlighted the potential involvement of reactive oxygen species (ROS) and microglia, a major source of ROS, in the pathophysiology of schizophrenia. In our study, we explored how the second‐generation antipsychotic risperidone (RIS) affects ROS regulation and microglial activation in the hippocampus using a mouse ketamine (KET) model of schizophrenia. KET administration resulted in schizophrenia‐like behaviors in male C57BL/6J mice, such as impaired prepulse inhibition (PPI) of the acoustic startle response and hyper‐locomotion. These behaviors were mitigated by RIS. We found that the gene expression level of an enzyme responsible for ROS production (Nox2), which is primarily associated with activated microglia, was lower in KET/RIS‐treated mice than in KET‐treated mice. Conversely, the levels of antioxidant enzymes (Ho‐1 and Gclc) were higher in KET/RIS‐treated mice. The microglial density in the hippocampus was increased in KET‐treated mice, which was counteracted by RIS. Hierarchical cluster analysis revealed three morphological subtypes of microglia. In control mice, most microglia were resting‐ramified (type I, 89.7%). KET administration shifted the microglial composition to moderately ramified (type II, 44.4%) and hyper‐ramified (type III, 25.0%). In KET/RIS‐treated mice, type II decreased to 32.0%, while type III increased to 34.0%. An in vitro ROS assay showed that KET increased ROS production in dissociated hippocampal microglia, and this effect was mitigated by RIS. Furthermore, we discovered that a NOX2 inhibitor could counteract KET‐induced behavioral deficits. These findings suggest that pharmacological inhibition of ROS production by RIS may play a crucial role in ameliorating schizophrenia‐related symptoms. Moreover, modulating microglial activation to regulate ROS production has emerged as a novel avenue for developing innovative treatments for schizophrenia.

Molecular mechanisms involved in the prevention and reversal of ketamine-induced schizophrenia-like behavior by rutin: the role of glutamic acid decarboxylase isoform-67, cholinergic, Nox-2-oxidative stress pathways in mice

Prevention and reversal of ketamine-induced experimental psychosis in mice by the neuroactive flavonoid, hesperidin: The role of oxidative and cholinergic mechanisms

Rutin prevents seizures in kainic acid-treated rats: evidence of glutamate levels, inflammation and neuronal loss modulation

Repeated Sub-anaesthetic dose of Ketamine Elevates Superoxide Dismutase in Pharmacological Model of Schizophrenia-Like Phenotypes in Mice

Effective Action of Silymarin against Ketamine-induced Schizophrenia in Male Mice: Insight into the Biochemical and Molecular Mechanisms of Action

Lipopolysaccharide Exacerbates Ketamine-Induced Psychotic-Like Behavior, Oxidative Stress, and Neuroinflammation in Mice: Ameliorative Effect of Diosmin

L-Carnitine Prevents Behavioural Alterations in Ketamine-Induced Schizophrenia in Mice: Possible Involvement of Oxidative Stress and Inflammation Pathways

Inhibition of reactive oxygen species production accompanying alternatively activated microglia by risperidone in a mouse ketamine model of schizophrenia

Neuroprotective effects of rutin against cuprizone-induced multiple sclerosis in mice

Rutin, A Natural Flavonoid Protects PC12 Cells Against Sodium Nitroprusside-Induced Neurotoxicity Through Activating PI3K/Akt/mTOR and ERK1/2 Pathway

Rutin via Increase in the CA3 Diameter of the Hippocampus Exerted Antidepressant-Like Effect in Mouse Model of Maternal Separation Stress: Possible Involvement of NMDA Receptors

NMDA receptor modulation by Esculetin: Investigating behavioral, biochemical and neurochemical effects in schizophrenic mice model

Rutin protects against trimethyltin-induced learning and memory impairment in BALB/c mice by antagonizing down-regulated synaptophysin expression

Benefits of rutin on mitochondrial function and inflammation in an aluminum-induced neurotoxicity rat model: Potential interest for the prevention of neurodegeneration

Neuronal injury, but not microglia activation, is associated with ketamine-induced experimental schizophrenic model in mice.

Reversal and Preventive Pleiotropic Mechanisms Involved in the Antipsychotic-Like Effect of Taurine, an Essential β-Amino Acid in Ketamine-Induced Experimental Schizophrenia in Mice

Rutin protects rat liver and kidney from sodium valproate-induce damage by attenuating oxidative stress, ER stress, inflammation, apoptosis and autophagy

Rutin Improves Spatial Memory in Alzheimer's Disease Transgenic Mice by Reducing Aβ Oligomer Level and Attenuating Oxidative Stress and Neuroinflammation

Reversal of Schizophrenia-Like Symptoms and Immune Alterations in Mice by Immunomodulatory Drugs.

Rutin prevents tau pathology and neuroinflammation in a mouse model of Alzheimer’s disease

Aflatoxin B1-induced redox imbalance in the hippocampus and cerebral cortex of male Wistar rats is accompanied by altered cholinergic, indoleaminergic, and purinergic pathways: Abatement by dietary rutin